QQ客服 官方微博 反馈留言

浏览/检索结果: 共6条，第1-6条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 REVISITING THE MOLLUSCAN FAUNA FROM THE CAMBRIAN (SERIES 2, STAGES 3-4) XINJI FORMATION OF NORTH CHINA 期刊论文 PAPERS IN PALAEONTOLOGY, 2019, 页码: 44 作者:  Li, Luoyang;  Zhang, Xingliang;  Skovsted, Christian B.;  Yun, Hao;  Pan, Bing （潘兵） 收藏  |  浏览/下载：7/0  |  提交时间：2020/03/18 Cambrian Series 2  North China  mollusc  taxonomy  muscle scar   Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*) 期刊论文 LEUKEMIA & LYMPHOMA, 2019, 卷号: 60, 期号: 1 作者:  Robak, Tadeusz;  Huang, Huiqiang;  Jin, Jie;  Zhu, Jun;  Liu, Ting 收藏  |  浏览/下载：24/0  |  提交时间：2019/12/05 Mantle cell lymphoma  R-CHOP  VR-CAP  bortezomib  LYM-3002  dose intensity   Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma 期刊论文 ONCOTARGETS AND THERAPY, 2018, 卷号: 11 作者:  Jin, Jie;  Okamoto, Rumiko;  Yoon, Sung-Soo;  Shih, Lee-Yung;  Zhu, Jun 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05 mantle-cell lymphoma  bortezomib  VR-CAP  R-CHOP   Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM-3002 study 期刊论文 Blood, 2014, 卷号: 124 作者:  Robak T., Huang H., Jin J., Zhu J., Liu T., Samoilova O.S., Pylypenko H., Verhoef G., Siritanaratkul N., Osmanov E.A., Alexeeva J., Pereira J., Mayer J., Hong X., Maeda Y., Pei L., Rooney B., Van De V 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/19 Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study 会议论文 作者:  Robak, Tadeusz;  Huang, Huiqiang;  Jin, Jie;  Zhu, Jun;  Liu, Ting 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/19 PHASE 3 STUDY OF FRONTLINE RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE PLUS VINCRISTINE (R-CHOP) OR BORTEZOMIB (VR-CAP) IN TRANSPLANTATION-UNSUITABLE MANTLE CELL LYMPHOMA (MCL) PATIENTS 会议论文 作者:  Robak, T.;  Huang, H.;  Jin, J.;  Zhu, J.;  Liu, T. 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/19